Study Discredits Mystery Brain Disease in New Brunswick

A recent peer-reviewed study has found no evidence of a mysterious brain disease in New Brunswick, Canada. Instead, the results suggest a troubling mix of “misdiagnosis and misinformation.”

This research arrives as the Maritime province is preparing to assess over 220 suspected cases, hoping to provide families with clarity regarding the medical enigma that has troubled the region for years.

Published in the Journal of the American Medical Association (JAMA), this report offers an independent review of 25 cases originally diagnosed by neurologist Alier Marrero from a larger group of 222 patients.

The researchers, associated with the University of Toronto and New Brunswick’s Horizon Health Network, concluded that many patients were misdiagnosed and actually suffered from common neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, along with functional neurological disorders and other known conditions.

However, these findings may not alleviate the concerns of families who suspect environmental contamination is to blame for their loved ones’ symptoms.

Health officials in New Brunswick first raised alarms in 2021 when over 40 residents showed signs of a potential unknown neurological syndrome, exhibiting symptoms similar to Creutzfeldt-Jakob disease.

These cases were forwarded to Marrero after their initial physicians struggled to identify the conditions. A year later, an independent oversight committee suggested that these patients were likely misdiagnosed and actually suffered from recognized ailments like cancer and dementia.

A final report from that committee determined there was no “cluster” of unknown brain syndrome cases, effectively closing the province’s investigation.

Earlier that same year, a federal scientist expressed concerns that something significant was happening in New Brunswick. Another claimed the investigation was “shut down” despite higher-than-reported caseloads, stating that they were ready to mobilize resources to delve deeper into the issue, but their efforts were declined.

In a letter from Marrero to federal and provincial officials, it was reported that the number of patients experiencing unexplained neurological symptoms had surged to 507 across several provinces, with some individuals under 45.

The new study found that all 25 cases involved well-known conditions like neurodegenerative diseases and traumatic brain injuries, reiterating that the likelihood of a new disease was extremely low, with a probability below .001.

Patient advocacy groups have resisted the notion of a new mystery illness, instead linking the cases to environmental contaminants. Nevertheless, the researchers dismissed the idea that exposure to substances like herbicides or heavy metals contributed to the patients’ conditions.

They noted that “misdiagnosis and misinformation often intertwine and exacerbate harm,” and pointed out that over half of those eligible for the study chose not to participate.

The researchers attributed the persistence of the “mystery illness” idea to “inaccurate clinical assessments” and an excessive reliance on additional testing, observing notable discrepancies in case histories.

Marrero expressed his profound disagreement with the conclusions of the study, questioning both the methods and content used, and stated he was “appalled” that a study based on such a small number of cases was conducted without his awareness.

Susan Holt, the province’s premier, promised a comprehensive new investigation when she took office last year. “I think we need to do everything we can to illuminate this issue and identify what’s making people ill,” she stated.

Dr. Yves Léger, New Brunswick’s chief medical officer of health, also mentioned that the JAMA study wouldn’t affect their ongoing investigation into the 222 cases that Marrero had officially referred.

Updates will be posted on the province’s website, with a public report containing recommendations expected in the coming months.